In Brief: Rx-to-OTC switch application fee revenues
This article was originally published in The Tan Sheet
Executive Summary
Rx-to-OTC switch application fee revenues: Expected to total $5 mil. under the President's proposed FY 1998 budget, FDA says in a Feb. 6 budget summary document. The Administration's fiscal 1998 budget proposal also calls for new fees for "medical device reviews, animal drug approvals, import inspections, food additive petition reviews, generic/over-the-counter applications and fees for postmarket surveillance of products." Nonprescription Drug Manufacturers Association President James Cope said in November that the association was "willing" to consider user fees for OTC drug monograph activities as it had during the 1991 negotiations for PDUFA...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning